Introduction

In one of the most consequential pharmaceutical patent disputes in recent memory, a Delaware federal jury delivered a split verdict in United States of America v. Gilead Sciences, Inc. (Case No. 1:19-cv-02103) — finding direct infringement of government-owned HIV prevention patents while simultaneously invalidating every asserted claim. The May 2023 jury verdict, formalized by the Delaware District Court on March 22, 2024, centers on two blockbuster HIV pre-exposure prophylaxis (PrEP) drugs: Truvada® for PrEP and Descovy® for PrEP, products generating billions in annual revenue for Gilead.

This HIV PrEP patent infringement case represents a rare instance of the U.S. federal government asserting patent rights against a private pharmaceutical company — and an equally rare outcome where infringement is proven yet rendered legally meaningless by successful invalidity defenses. For patent attorneys, IP professionals, and R&D decision-makers navigating pharmaceutical patent litigation, this case delivers critical lessons on prosecution strategy, validity challenges, and the interplay between infringement findings and patent enforceability.

Case Overview

The Parties

The Patents at Issue

Three patents were actively asserted at trial, covering methods of using tenofovir-based regimens for HIV prophylaxis. A fourth patent was also involved in the proceeding:

• • U.S. Patent No. 9,579,333 (App. No. 14/679,887) — Claim 13 asserted
• • U.S. Patent No. 9,937,191 (App. No. 15/406,344) — Claim 18 asserted
• • U.S. Patent No. 10,335,423 (App. No. 10/335,423) — Claim 18 asserted
• • U.S. Patent No. 9,044,509 (App. No. 11/669,547)

The Accused Products

Gilead’s Truvada® (emtricitabine/tenofovir disoproxil fumarate) and Descovy® (emtricitabine/tenofovir alafenamide) were accused of infringing the government’s PrEP method patents when used as directed for pre-exposure prophylaxis. Both products carry FDA-approved PrEP indications, making their commercial use directly relevant to the asserted method claims.

Legal Representation

The government was represented by the U.S. Attorney’s Office, with attorney Laura D. Hatcher leading counsel. Gilead assembled a formidable defense team anchored by Richards, Layton & Finger, PA, alongside attorneys including Frederick L. Cottrell III, Ronald C. Machen, Mark C. Fleming, David B. Bassett, and Emily R. Whelan, among fifteen total defense counsel.

Litigation Timeline & Procedural History

Filed on November 6, 2019, this case spans approximately four years and four months through its formal close on March 22, 2024 — a duration typical of complex pharmaceutical patent litigation involving multiple patents, extensive claim construction proceedings, and a full jury trial.

Venued in the U.S. District Court for the District of Delaware — the preeminent forum for pharmaceutical patent disputes — the case proceeded as a first-instance district court action. Delaware’s experienced patent bench and established precedent in Hatch-Waxman and pharmaceutical IP litigation made it a natural, if contested, venue.

The case reached a jury trial, with the jury rendering its unanimous verdict on May 9, 2023 (D.I. 468, 469). The court’s formal judgment under Rule 58(b) of the Federal Rules of Civil Procedure was entered nearly ten months later on March 22, 2024, with deadlines for attorneys’ fees motions (including under 35 U.S.C. § 285) extended pending appeal resolution.

The Verdict & Legal Analysis

Outcome: A Legally Neutralized Infringement Finding

The jury returned a mixed judgment — arguably the most complex outcome available in patent litigation:

1. Direct infringement confirmed for both Truvada® for PrEP and Descovy® for PrEP on all asserted claims (Claim 13 of the ‘333 Patent; Claim 18 of the ‘191 Patent; Claim 18 of the ‘423 Patent).
2. All asserted claims invalidated on grounds of anticipation and obviousness.
3. Claim 18 of the ‘423 Patent was additionally invalidated for lack of enablement — a separate and significant basis of invalidity.

No damages figure was awarded given the invalidity findings. The court extended attorneys’ fees deadlines pending appeal, signaling further proceedings are anticipated.

Verdict Cause Analysis

Invalidity Defenses Prevailed Comprehensively. Gilead successfully argued that the government’s asserted claims were anticipated by prior art and obvious — meaning the claimed PrEP methods were either already disclosed in prior publications or would have been obvious to a skilled practitioner at the time of invention. This defense is particularly potent against method patents covering established scientific approaches, where the gap between prior research and the claimed invention can be difficult to articulate.

Enablement Failure on Claim 18 of the ‘423 Patent. The additional invalidity finding for lack of enablement under 35 U.S.C. § 112 suggests the patent’s written description failed to enable a person skilled in the art to practice the full scope of Claim 18 without undue experimentation — a significant prosecution red flag.

Infringement Nonetheless Established. The jury’s willingness to find infringement despite invalidating the claims illustrates the independence of infringement and validity analyses under U.S. patent law. For practitioners, this confirms that claim drafting must survive validity scrutiny as much as it must capture accused products.

Legal Significance

This case reinforces several critical doctrines:

• • Anticipation and obviousness remain the most powerful invalidity tools against method patents in established therapeutic areas
• • Enablement challenges deserve serious prosecution attention, particularly for claims with broad functional scope
• • Government patent assertion carries unique considerations — the U.S. cannot be enjoined in the traditional sense, and damages against the government are governed by 28 U.S.C. § 1498, not standard patent damages frameworks

Strategic Takeaways

For Patent Holders: Ensure continuation prosecution strategies stress-test claims against the known prior art landscape. Overly broad method claims in well-researched therapeutic areas are vulnerable targets.

For Accused Infringers: A multi-pronged invalidity strategy (anticipation + obviousness + enablement) is more robust than reliance on any single ground. Gilead’s comprehensive defense team demonstrates the value of deep resources in high-stakes pharmaceutical patent litigation.

For R&D Teams: FDA-approved product labeling that directly mirrors patent claim language creates heightened infringement exposure. PrEP indication language should be reviewed against competitor patent portfolios as part of ongoing FTO (freedom-to-operate) analysis.

Industry & Competitive Implications

The government’s assertion of CDC-held patents against a commercial PrEP manufacturer has significant policy dimensions. Federal agencies increasingly recognize their patent portfolios as enforcement assets, creating a new litigation risk vector for pharmaceutical companies that commercialize products built on federally funded research.

For Gilead, the invalidity outcome protects its dominant PrEP market position — worth an estimated $2–3 billion annually in U.S. revenue at peak Truvada® sales — from royalty obligations to the government. However, the infringement finding, even without damages, creates a public record with implications for legislative scrutiny of drug pricing versus federal R&D investment.

Broader pharmaceutical industry implications include renewed attention to invention disclosure practices in academic-government research collaborations and the vulnerability of early-stage method patents when clinical research was widely ongoing before patent filing. Companies conducting FTO analyses for antiretroviral or prophylaxis products should evaluate government-held patent portfolios alongside private assignee IP.